Armour Thyroid Re-Titration After Stopping

Why You Cannot Simply Resume Your Old Dose

Stopping Armour Thyroid for more than a few weeks allows the HPT axis to recalibrate. The pituitary increases TSH secretion, peripheral deiodinase activity shifts, and thyroid hormone receptor sensitivity changes. Jumping straight back to a full replacement dose floods a system that has adapted to lower hormone levels.

HPT Axis Reset Mechanics

Thyroid hormone replacement suppresses endogenous TSH production through negative feedback at the pituitary and hypothalamus 1. When exogenous hormone is removed, TSH rises over days to weeks, but the downstream receptor field takes longer to readjust. Abrupt reintroduction of 60 to 120 mg of desiccated thyroid delivers both T4 and T3 simultaneously. The T3 component (approximately 9 mcg per grain) has a half-life of only about 1 day, creating rapid peaks that a de-adapted cardiovascular system may not tolerate well 2.

Cardiac and Adrenal Risk

The American Thyroid Association (ATA) 2014 guidelines note that patients with cardiac disease or prolonged hypothyroidism should start thyroid replacement at 12.5 to 25 mcg of levothyroxine equivalent and titrate slowly 1. This principle applies equally to desiccated thyroid. Excess T3 exposure can provoke tachycardia, atrial fibrillation, and angina. Patients with marginal adrenal reserve face an additional risk: thyroid hormone accelerates cortisol clearance, and restarting at full dose without adequate cortisol output can precipitate an adrenal crisis 3.

Recommended Re-Titration Protocol

Start low. Go slow. The protocol below applies to adults without significant cardiac history who previously tolerated Armour Thyroid at a stable dose and stopped for four or more weeks.

Step 1: Baseline Labs Before Restarting

Draw TSH, free T4, free T3, and (if not recently checked) a morning cortisol or ACTH stimulation test before writing the first prescription. The ATA recommends confirming hypothyroidism with repeat TSH measurement before initiating therapy 1. If TSH is only mildly elevated (4.5 to 10 mIU/L), the decision to restart should weigh symptoms against the risks of treatment.

Step 2: Initial Dose Selection

For most adults, begin at 15 to 30 mg (0.25 to 0.5 grain) once daily on an empty stomach, 30 to 60 minutes before breakfast. The FDA-approved labeling for Armour Thyroid recommends a starting dose of 30 mg for uncomplicated hypothyroidism, with lower starting doses for patients with cardiovascular disease or longstanding myxedema 4. Patients over 65 or those with known coronary artery disease should start at 15 mg.

Step 3: Dose Escalation Schedule

Increase by 15 mg every 4 to 6 weeks based on TSH, free T4, and free T3 results. A typical escalation looks like this:

| Week | Daily Dose | Lab Check | |------|-----------|-----------| | 0 | 15 to 30 mg | Baseline drawn before start | | 4 to 6 | 30 to 45 mg | TSH, free T4, free T3 | | 8 to 12 | 45 to 60 mg | TSH, free T4, free T3 | | 12 to 18 | 60 to 90 mg | TSH, free T4, free T3 | | 16 to 24 | 90 to 120 mg | TSH, free T4, free T3 |

Not every patient needs to reach 120 mg. Target the lowest dose that normalizes TSH (typically 0.5 to 2.5 mIU/L) and resolves symptoms.

Step 4: When to Hold Dose Increases

Pause escalation if free T3 exceeds the upper reference range, resting heart rate climbs above 90 bpm at rest, or the patient reports palpitations, tremor, or heat intolerance. These signs suggest T3 excess from the desiccated thyroid formulation. In Hoang et al.'s crossover trial (N=70), patients on desiccated thyroid extract lost an average of 3 lb more than those on levothyroxine, but a subset developed suppressed TSH values below 0.5 mIU/L, requiring dose reduction 2.

How Armour Thyroid Differs from Levothyroxine Re-Titration

The dual-hormone composition of desiccated thyroid (T4 plus T3) makes re-titration distinct from restarting levothyroxine alone. This difference affects monitoring, timing, and risk.

The T3 Factor

Each grain (60 mg) of Armour Thyroid delivers approximately 38 mcg of T4 and 9 mcg of T3 4. The T4:T3 ratio in human thyroid secretion is roughly 14:1 by mole, while desiccated thyroid provides a ratio closer to 4.2:1. This supraphysiologic T3 proportion means free T3 peaks 2 to 4 hours after ingestion. Dr. Antonio Bianco, an endocrinologist at the University of Chicago and past president of the American Thyroid Association, has stated: "The T3 in desiccated thyroid creates a pharmacokinetic profile quite different from what the normal thyroid gland produces, with peak-to-trough swings that synthetic T4 monotherapy avoids" 5.

Lab Timing Matters More

Because of T3 peaks, draw labs at least 8 to 12 hours after the last Armour Thyroid dose to avoid measuring a transient T3 spike that does not reflect steady-state levels 1. Morning dosing with next-morning labs works well. A blood draw 2 to 4 hours post-dose will show artificially elevated free T3 and may lead to inappropriate dose reductions.

Switching from Levothyroxine to Armour During Re-Titration

Some patients who previously took Armour Thyroid were switched to levothyroxine during their gap. If converting back, a commonly used (though imprecise) equivalence is 1 grain (60 mg) of desiccated thyroid to roughly 88 to 100 mcg of levothyroxine 6. Still, start at 0.5 grain and titrate. The conversion factor varies between individuals due to differences in T4-to-T3 conversion efficiency (deiodinase polymorphisms), absorption, and binding protein levels.

Duration of the Gap: Does It Change the Protocol?

Yes. The length of time off Armour Thyroid influences how aggressively you need to reset.

Short Gaps (Under 2 Weeks)

If a patient missed doses for fewer than 14 days, resuming at the previous dose is generally acceptable. The T4 component has a half-life of 6 to 7 days, so residual hormone remains in circulation 7. Recheck labs 6 weeks after resuming.

Moderate Gaps (2 to 8 Weeks)

Start at 50% to 75% of the previous maintenance dose. After 2 weeks off therapy, serum T4 levels have dropped substantially, and TSH has risen. The axis is partially reset but retains some adaptation. A 6-week lab check determines whether escalation is needed.

Long Gaps (Over 8 Weeks)

Treat this as a new start. Begin at 15 to 30 mg regardless of the prior stable dose. After 8 weeks without exogenous thyroid hormone, the HPT axis has fully recalibrated, peripheral tissue responsiveness has shifted, and the patient's clinical picture may have changed (weight gain, altered renal function, new medications). In a retrospective cohort of 1,222 hypothyroid patients who discontinued levothyroxine, Mammen et al. Found that 37% had a TSH above 10 mIU/L by 8 weeks 8.

Special Populations Requiring Modified Titration

Not all patients follow the standard escalation. Several groups require adjusted starting doses or closer monitoring.

Elderly Patients (Over 65)

Start at 15 mg daily. The 2014 ATA guidelines recommend beginning at the lowest available dose in older adults due to reduced cardiac reserve and higher prevalence of subclinical coronary artery disease 1. Increase by 15 mg every 6 to 8 weeks rather than every 4 weeks.

Patients with Cardiovascular Disease

The FDA label for Armour Thyroid warns that thyroid hormones should be used with "great caution" in patients with angina pectoris or other cardiovascular disease 4. Start at 15 mg. Some clinicians prefer levothyroxine monotherapy in this population because it avoids T3 peaks. If the patient strongly prefers desiccated thyroid, split dosing (half the daily dose in the morning, half in the early afternoon) can blunt T3 spikes, though this strategy lacks formal trial data.

Patients with Adrenal Insufficiency

Evaluate and treat cortisol deficiency before restarting any thyroid hormone. The Endocrine Society's clinical practice guideline on adrenal insufficiency states: "Thyroid hormone replacement should not be initiated until glucocorticoid replacement is established, as thyroid hormone accelerates cortisol metabolism and may precipitate adrenal crisis" 3. Once cortisol replacement is stable, begin Armour Thyroid at 15 mg and titrate with standard intervals.

Post-Thyroidectomy and RAI-Ablated Patients

Patients who have no residual thyroid function will ultimately require full replacement (often 1.5 to 2 grains, depending on body weight). The re-titration protocol remains the same: start low and escalate every 4 to 6 weeks. These patients have zero endogenous production to buffer dose changes, so symptoms of both under- and over-replacement tend to be more pronounced.

Monitoring Beyond TSH

TSH alone is insufficient for managing desiccated thyroid therapy. A panel approach catches problems that TSH misses.

Recommended Lab Panel

At each titration visit, order TSH, free T4, and free T3 at minimum. The ATA acknowledges that some patients on combination T4/T3 therapy may show suppressed TSH with normal free T4 and free T3, which does not necessarily indicate overtreatment 1. Consider adding reverse T3 if the patient reports persistent hypothyroid symptoms despite normal TSH.

Symptom Tracking

Quantitative symptom tools like the Billewicz score or the ThyPRO-39 questionnaire can help objectify subjective complaints during titration 9. Track fatigue, cold intolerance, constipation, weight changes, heart rate, and mood at each visit.

Bone and Cardiac Surveillance

Long-term TSH suppression (below 0.1 mIU/L) increases fracture risk in postmenopausal women. A meta-analysis by Blum et al. (N=5,458) found a 1.9-fold increase in fracture risk in patients with suppressed TSH receiving thyroid hormone 10. For patients over 50, consider a baseline DEXA scan if TSH remains suppressed after titration. ECG monitoring is reasonable for patients over 65 or those with cardiac risk factors.

Common Mistakes During Re-Titration

Clinicians and patients both make predictable errors when restarting desiccated thyroid. Avoiding these accelerates time to stable dosing.

Resuming the Full Previous Dose

This is the most common error. A patient who was stable on 90 mg for years assumes the same dose is still correct. But body composition, renal clearance, estrogen levels, and concurrent medications may have changed during the gap. Even if the prior dose turns out to be correct, the safe path is to arrive at it through measured escalation.

Drawing Labs Too Early or at Wrong Times

Checking TSH at 2 weeks post-dose-change captures a moving target. The T4 component needs 5 to 6 half-lives (roughly 5 to 6 weeks) to reach steady state 7. Labs drawn at 2 weeks underestimate the eventual TSH suppression and may prompt premature dose increases. Always wait at least 4 weeks, and draw blood before the morning dose.

Ignoring Drug Interactions

Calcium supplements, iron, proton pump inhibitors, and cholestyramine all reduce thyroid hormone absorption. The ATA guidelines recommend spacing calcium and iron supplements at least 4 hours from thyroid hormone ingestion 1. New medications added during the gap period deserve specific attention.

What to Expect: Timeline for Symptom Improvement

Patients want to know when they will feel better. Setting realistic expectations reduces anxiety and premature dose changes.

T3-mediated symptoms (energy, brain fog, mood) often improve within the first 1 to 2 weeks of restarting because T3 acts rapidly at the nuclear receptor level. T4-mediated effects (hair regrowth, skin changes, cholesterol normalization) take 8 to 12 weeks because T4 must convert to T3 intracellularly and downstream tissue remodeling is slow. Full symptom resolution at the final maintenance dose typically takes 3 to 6 months from the date of restart.

In Hoang et al.'s trial comparing desiccated thyroid to levothyroxine, 48.6% of patients preferred desiccated thyroid and reported greater satisfaction, though objective cognitive and quality-of-life scores did not differ significantly between groups 2. Patient preference is a valid factor in thyroid therapy selection, but it does not override the need for careful titration.

For patients restarting after a gap of 8 weeks or longer on a 15 mg starting dose, expect to reach a typical maintenance dose of 60 to 90 mg in approximately 12 to 18 weeks, assuming 4-week titration intervals and no complications requiring dose holds.